MiniMed Group (NASDAQ:MMED) Stock Price Target Raised at Mizuho

Key Points

• Mizuho raised MiniMed Group’s price target from $26 to $28 and maintained an “outperform” rating, implying 46.52% potential upside from the current share price.
• Analyst sentiment is broadly positive: 13 analysts rate the stock Buy, three rate it Hold, and one rates it Sell, resulting in a consensus “Moderate Buy” rating and a $24 average target.
• MMED shares opened at $19.11 after falling 2.7%; meanwhile, major institutions increased their positions, led by BlackRock’s 7,527.5% increase during the second quarter.

MiniMed Group (NASDAQ:MMED - Get Free Report) had its target price raised by analysts at Mizuho from $26.00 to $28.00 in a report released on Thursday, Benzinga reports. The firm currently has an "outperform" rating on the stock. Mizuho's price objective suggests a potential upside of 46.52% from the stock's current price.

MMED has been the subject of a number of other reports. Weiss Ratings raised shares of MiniMed Group from a "sell (d-)" rating to a "sell (d)" rating in a research note on Wednesday, September 9th. UBS Group boosted their price target on MiniMed Group from $25.00 to $28.00 and gave the company a "buy" rating in a report on Wednesday, September 2nd. BTIG Research upped their price objective on MiniMed Group from $25.00 to $28.00 and gave the stock a "buy" rating in a research report on Tuesday, September 1st. Bank of America increased their price objective on MiniMed Group from $24.00 to $28.00 and gave the stock a "buy" rating in a report on Wednesday, September 2nd. Finally, Citigroup boosted their target price on MiniMed Group from $23.00 to $26.00 and gave the company a "buy" rating in a research note on Wednesday, September 2nd. Thirteen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $24.00.

MiniMed Group Stock Down 2.7%

MiniMed Group stock opened at $19.11 on Thursday. The company has a 50 day moving average of $20.57 and a 200-day moving average of $16.38. MiniMed Group has a twelve month low of $10.65 and a twelve month high of $24.43. The stock has a market capitalization of $5.38 billion and a PE ratio of -28.10.

Hedge Funds Weigh In On MiniMed Group

Hedge funds have recently modified their holdings of the stock. BlackRock Inc. increased its position in shares of MiniMed Group by 7,527.5% in the second quarter. BlackRock Inc. now owns 1,996,489 shares of the company's stock valued at $29,848,000 after acquiring an additional 1,970,314 shares during the last quarter. J. Goldman & Co LP bought a new position in MiniMed Group in the second quarter valued at approximately $12,412,000. State Street Corp acquired a new position in shares of MiniMed Group during the 2nd quarter worth approximately $6,029,000. Readystate Asset Management LP bought a new stake in shares of MiniMed Group during the 2nd quarter worth approximately $4,400,000. Finally, Bank of America Corp DE boosted its holdings in shares of MiniMed Group by 377.0% in the 2nd quarter. Bank of America Corp DE now owns 238,819 shares of the company's stock valued at $3,570,000 after buying an additional 188,756 shares during the last quarter.

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.